Epitopea Doses First Patient With an Off-the-Shelf mRNA Cancer Vaccine
Epitopea's first-in-human OVACT trial has dosed a patient with CryptiVax-1001, an mRNA vaccine built on dark-genome antigens. The milestone confirms execution, not efficacy; the registry points to a 2029 primary completion.